Clinical Trials Logo

Clinical Trial Summary

Melasma is a fairly common condition resulting in hyperpigmented macules on the face. Melasma is difficult to treat and has a significant negative impact on the patient's quality of life.

Melasma is worsen when exposed to high energy visible light (blue and violet light) of the solar spectrum. Blue light emitted by LED screens from computers, tablets, televisions and even mobile phones is currently suspected (via media channels) to induce harmful effects on the skin, including pigmentation and photoaging. These screens, however, emit much lower irradiances than those of the solar spectrum, and the probability that these irradiances impact the skin is very low.

The objective of the study is to assess the effect of blue light emitted by computer/television screens on the intensity of melasma pigmentation. To do this, it is proposed to use maximized conditions that could be encountered in normal daily life, namely a simulation of blue light exposure (420-490nm) at 20 cm from a laptop LED screen, 8 hours a day for 5 days. Since it is not proposed to expose a person for 8 hours a day, a solar simulator with appropriate filters will be used to emit a spectrum of between 420 and 490 nm with a compatible intensity for an acceptable duration of exposure (around 30 minutes a day).

Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified MASI on standardized photographs. A final evaluation visit will be performed at Day 15.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03877445
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact
Status Completed
Phase N/A
Start date April 11, 2019
Completion date July 22, 2019

See also
  Status Clinical Trial Phase
Completed NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma N/A
Recruiting NCT06174545 - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma N/A
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Recruiting NCT06278948 - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma N/A
Not yet recruiting NCT05911698 - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. N/A
Recruiting NCT05656833 - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma N/A
Recruiting NCT04597203 - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Terminated NCT03415685 - Lutronic PicoPlus Exploratory Clinical Trial N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Completed NCT04137263 - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging N/A
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT05969587 - Cysteamine Compared to Hydroquinone in Melasma Phase 3
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT05884151 - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Phase 1
Completed NCT05887219 - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Phase 1
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3